US 11,723,858 B2
Topical antiviral compositions, delivery systems, and methods of using the same
Kimberly McHale, Hillsborough, NC (US); Ryan Doxey, Raleigh, NC (US); and Nathan Stasko, Chapel Hill, NC (US)
Assigned to Novan, Inc., Durham, NC (US)
Filed by Novan, Inc., Durham, NC (US)
Filed on May 25, 2021, as Appl. No. 17/329,587.
Application 17/329,587 is a continuation of application No. 16/840,657, filed on Apr. 6, 2020, granted, now 11,040,006.
Application 16/840,657 is a continuation of application No. 16/431,214, filed on Jun. 4, 2019, granted, now 10,736,839, issued on Aug. 11, 2020.
Application 16/431,214 is a continuation of application No. 15/713,185, filed on Sep. 22, 2017, granted, now 10,322,082, issued on Jun. 18, 2019.
Application 15/713,185 is a continuation in part of application No. 15/324,332, granted, now 10,322,081, issued on Jun. 18, 2019, previously published as PCT/US2015/039908, filed on Jul. 10, 2015.
Application 15/713,185 is a continuation of application No. PCT/US2016/012668, filed on Jan. 8, 2016.
Application PCT/US2016/012668 is a continuation in part of application No. PCT/US2015/039908, filed on Jul. 10, 2015.
Claims priority of provisional application 62/139,176, filed on Mar. 27, 2015.
Claims priority of provisional application 62/023,587, filed on Jul. 11, 2014.
Prior Publication US 2021/0346280 A1, Nov. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 33/00 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/02 (2006.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01); A61K 47/24 (2006.01); A61K 9/06 (2006.01); A61K 31/675 (2006.01)
CPC A61K 9/0014 (2013.01) [A61K 9/06 (2013.01); A61K 31/675 (2013.01); A61K 33/00 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 20 Claims
 
1. A delivery system comprising a composition, the composition comprising a nitric oxide (NO)-releasing active pharmaceutical ingredient,
wherein the NO-releasing active pharmaceutical ingredient is a diazeniumdiolated co-condensed silica particle and is present in the composition in an amount of 0.01% to 30% by weight of the composition,
wherein the composition has a Cmax of greater than 160 pmol of NO/mg, as measured by in vitro release testing, and
wherein the composition has a pH of about 5 to about 8.